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A commentary on
Interaction of the ADRB2 gene polymorphism with childhood trauma in predicting adult
symptoms of posttraumatic stress disorder
by Liberzon I, King AP, Ressler KJ, Almli LM, Zhang P, Ma ST, et al. JAMA Psychiatry (2014)
71:1174–82. doi:10.1001/jamapsychiatry.2014.999
While posttraumatic stress disorder (PTSD) is relatively common among psychiatric conditions, it
only emerges in a subpopulation of persons exposed to environmental trauma (1). Brain noradren-
ergic system dysfunction has been implicated in development of PTSD (2). However, unknown is
the extent to which polymorphisms in brain noradrenergic system genes interact with childhood
environmental trauma to alter resilience or vulnerability to developing PTSD in adulthood.
Using a cohort of predominantly male military veterans and another with predominantly female
civilians, Liberzon et al. found that individuals with a beta2-adrenergic receptor (ADRB2) gene
variant and childhood trauma are at heightened risk for adult PTSD (3). Interestingly, ADRB2
polymorphism has also been associated with a risk for the development of chronic pain (4). Another
ADRB2 gene variant was associated with resilience to adult PTSD symptoms (3). Collectively, these
findings suggest that ADRB2 gene variants affecting brain noradrenergic system function interact
with childhood adversity to alter vulnerability or resilience to development of PTSD. Replication
of this research in large cohorts is needed as well as physiological confirmation of abnormal
noradrenergic system function (3).
Noradrenergic system dysfunction has also been implicated in increased susceptibility to stress-
induced opioid use and craving in individuals with opioid use disorders (OUD) (5). Furthermore,
PTSD frequently co-occurs with OUD (6, 7). Thus, research should prospectively investigate
whether similar gene by childhood-adversity interactions heighten vulnerability to developing
co-occurring PTSD and OUD.
One limitation of this study is insufficient information to determine whether it accounts for
epigenetic and associated brain vulnerability factors from such childhood trauma that may also pre-
dispose to developing PTSD. It is difficult to determine whether this study controlled for pertinent
non-specific neurobiological factors indirectly impacting response to trauma in a particular person,
independent of this gene by environmental-adversity interaction. It is also unclear whether altered
expression of this gene is tangential/incidental to co-occurring critical brain development changes
altering PTSD vulnerability.
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To substantively advance knowledge, longitudinal research
with sufficient statistical power is needed using advances in
neuropsychiatric imaging and bioinformatics to identify brain
genetic variants, imaging, pharmacogenetic and other molecular
biomarkers, and neuropsychiatric vulnerability factors interacting
with traumatic environmental events in childhood to predict long-
term departures from normal brain and cognitive development,
associated with PTSD and/or chronic pain. Such research should
also identify critical brain and cognitive development windows
in prodromal stages where primary prevention approaches might
particularly be targeted to prevent the onset of PTSD and co-
occurringOUD. For such a study to be impactful, it should include
a large heterogeneous sample representative of the population of
interest, control for relevant developmental, socio-demographic,
psychiatric, environmental, and family-history cofactors, and
include validated patient-reported and clinician-measured out-
comes of PTSD and OUD. Sampling designs using probability-
based sampling of subgroups at greater risk for PTSD and OUD
(e.g., positive family history, prenatal exposure to substances of
abuse, externalizing psychopathology) may be needed to achieve
the above objectives. A reasonable research approach may also
incorporate genetically informative designs (for instance, family
based) or subjects (for instance, twins, siblings).
To address these considerations, suitable research settings
could be large healthcare system-based research networks con-
taining existing electronic health record systems (EHRs) and
virtual data warehouses, which routinely and in a consistent
manner capture comprehensive longitudinal health data on a
relevant population base of patients, which can be combined
with genetic and environmental data from longitudinal-cohort
research studies. Leveraging interoperable EHRs in such practice-
based research networks can enhance recruitment time as well
as allowing efficient and cost-efficient targeting of research sub-
jects with relevant characteristics (8). Furthermore, standard-
ized data collection, querying, extraction and storage procedures
are needed to return clinical data in a consistent manner to
a centralized repository and to permit semantic mapping to
achieve health information interoperability. In addition, state-
of-the-art data-collection procedures (for instance, computer-
administered/assisted interviews), practices (for instance, cultural
matching) and quality-control processes (for instance, random
verification, logic-checking) should be used. Much could be
learned using this “big-data science” approach in such research
networks to identify critical gene by environmentmediated devel-
opment patterns of PTSD, co-occurring OUD, and remission, and
efficiently targeting the above longitudinal research objective to
relevant subgroups of patients. For such research to have potential
for optimizing care tailored to specific patient subgroups (i.e.,
precision medicine), it should ultimately establish EHRs-based
expert-defined, actionable clinical decision support (CDS) tools
that could assist medical providers to identify and manage patient
subgroups with PTSD, and common co-occurring conditions,
such as chronic pain and opioid misuse/use disorder, in gen-
eral medical settings. Actionable CDS tools for managing co-
occurring PTSD andOUD should include validated screening and
assessment tools, which could be utilized to help clinicians in the
screening, identification, intervention or referral to treatment of
PTSD and OUD in general medical settings, results of which can
be incorporated into EHRs.
To conclude, to fill important precision-medicine research gaps
described above, large practice-based research networks with
standardized EHRs data collection, querying, extraction, and stor-
age approaches are needed to collect and analyze relevant lon-
gitudinal data on large numbers of individuals with important
phenotypic data to merge with genetic information. This could
be efficiently accomplished by such systems having the facilities
for, and expertise with, harmonized data collection and analy-
sis of neuropsychiatric imaging data and genetic specimens for
research, with accompanying patient-reported data routinely col-
lected in clinical practice and EHRs/encounter data. For example,
several practice-based research networks in the United States (9,
10) may be helpful, having extensive experience with using EHRs
to identify, recruit, and consent suitable patients and providers
in population-based samples, selected according to diagnosis,
patient-reported measures collected in clinical practice, treat-
ments received, utilization patterns, or socio-demographic char-
acteristics. Conducting this type of big-data longitudinal research
maximizes the potential to understand key brain vulnerability
factors interacting with early childhood adversity to alter sus-
ceptibility to PTSD and co-occurring OUD. Knowledge of such
information on neural mechanisms of PTSD and comorbid OUD
is a precursor to developing patient-centered, precision-medicine
approaches tailoring primary prevention and early intervention to
high-risk patients who may benefit from them the most.
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